July 13, 2021 • 3:00 PM - 4:00 PM ET

Angela Bakker Lee joined SomaLogic in 2020 as Executive Vice President for Healthcare Markets. She brings decades of experience in strategy and leading teams to successfully commercialize new digital technologies built on advances in artificial intelligence (AI) and machine learning.

Dr. Bakker Lee most recently served as Chief Strategy Officer for Quid, an AI text analytics platform provider, where she led global and strategic partnerships for clients such as Novartis and Walmart. Prior to Quid, she led IBM’s Global Business Services Healthcare for North America where she played a critical role advising on the launch of Watson Health, IBM’s first AI-focused business unit, including the business case, due diligence and integration efforts surrounding the acquisition of Truven Health Analytics. She also led IBM’s partnership with Apple to create mobile apps for healthcare clients to improve outcomes, reduce costs and enhance the interactive patient-provider experience. Prior to IBM, she spent 15 years with ZS Associates, a management consulting firm specializing in commercial strategy and sales and marketing operations, where she held a variety of leadership roles serving clients in both life sciences and healthcare.

Dr. Bakker Lee began her career in healthcare at Molecular Applications Group, a bioinformatics company in the Bay Area, after receiving a doctorate in immunology as a Marshall Scholar in the UK. She holds a bachelor’s degree from Stanford University.

Mike McGarry is the Director of Business Development at CU Innovations where he leads the business development team for the University of Colorado Anschutz Medical Campus. Mike’s responsibilities include the formation and management of strategic industry partnerships, and the development of long-term growth strategies for CUI. Mike joins CU Innovations with over 20 years of experience in the pharmaceutical and biotech industries, spanning functions such as business development, marketing, sales, market research, IT systems, and finance. Prior to CU Innovations, Mike was at Genentech for 11 years where he led sales and marketing teams, driving the adoption of precision medicines and immunotherapies in oncology. Prior to Genentech, Mike held roles across start-up companies and large companies alike, touching a variety of therapeutic areas in pharmaceutical, medical devices and telehealth industries.

Clay Smith, MD is the Director of the Blood Disorders and Cell Therapies Center at UCHealth. This program delivers and advances care for patients with blood cancers, general hematologic disorders and those undergoing treatment with blood and marrow stem cell transplants and CAR T-cells throughout the Rocky Mountain region. He also serves as the Associate Chief of the Division of Hematology at the University of Colorado (CU) and until recently was the Medical Director of the CU Hematology Clinical Trials Unit. He is a Professor at the University of Colorado, holds the Ruth and Ralph Seligman Chair in Hematology and his current academic focus is on developing and implementing precision medicine approaches for leukemia, CAR T-cells and other blood cancers. He is also the Medical Director for both the UCHealth and CU Innovations Centers, which serve as the primary interface for both organizations with pharma and other industries.

Dr. Smith was an undergraduate at Rice University, attended medical school at the University of Texas/Southwestern, trained as a resident and fellow at Cornell/NY Hospital and Sloan Kettering Cancer Center and undertook a specialty fellowship in blood and marrow transplantation at Stanford University. He has been on the faculty of Sloan Kettering, Duke University, Moffitt Cancer Center, the University of British Columbia/BC Cancer Agency and the University of Pittsburgh prior to coming to CU/UCHealth 9 years ago. He has had a funded laboratory for >30 years focused on gene and cell therapies, normal and malignant stem cells and most recently on the intersection of omics technologies and informatics as applied to hematologic malignancies and cellular therapies. He has over 20 years of leadership experience in directing malignant hematology and bone marrow transplant programs as well as their clinical trials units and has extensive experience in developing and conducting Phase I/II trials of innovation therapies. At the BC Cancer Agency, he chaired the Tumor Group Council which oversaw many aspects of cancer care delivery to the population of British Columbia in a universal health care system. He has authored >150 manuscripts, received dozens of grants, holds numerous patents, has helped found or consulted with numerous companies and has received a number of awards including the CU Department of Medicine Innovator of the Year award. In his spare time, he tends to 4 huskies, skis, cooks, is a part-time pilot and tries to play the guitar.